Key result
Intravenous peramivir, along with pericardial effusion drainage and steroids, improved clinical status without side effects in a toddler with influenza A myopericarditis and tamponade.
Case Report (n=1)
Intravenous peramivir can be safely and effectively used as part of the treatment for pediatric influenza A myopericarditis with tamponade.
Peramivir use improved status without side effects in this case; hypothesis-generating for pediatric influenza myopericarditis and requires prospective validation.
Peramivir is the only intravenous (IV) formulation among the anti-influenza neuraminidase (NA) inhibitor compounds currently available. On December 19, 2014, the US Food and Drug Administration approved peramivir to treat influenza infection in adults. We report a pediatric case with influenza A myopericarditis with tamponade, where use of peramivir along with pericardial effusion drainage and steroid administration improved clinical status without any side effects of the medication. To our knowledge, this is the first case in the United States where peramivir was used for complicated influenza A infection in a pediatric case since the 2009 H1N1 pandemic.
No takes yet. Share an insight, caveat, or question.
Chaudhary et al. (2015) conducted a case report in Influenza A myopericarditis with tamponade (n=1). Intravenous peramivir was evaluated on Clinical status improvement and side effects. Intravenous peramivir, along with pericardial effusion drainage and steroids, improved clinical status without side effects in a toddler with influenza A myopericarditis and tamponade.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: